Continuing Application:

Continuation

Continuation-in-part (CIP)

Divisional

Attorney Reference Number 4239-61997

PATENT

EXPRESS MAIL LABEL NO. EV

DATE OF DEPOSIT: February 6, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BOX PATENT APPLICATION COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Transmitted herewith for filing is the continuing patent application of:

Inventor(s): Dennis M. Klinman, Daniela Verthelyi, Ken Ishii, James J. Mond, Mayda Gursel

For: OLIGODEOXYNUCLEOTIDE AND ITS USE TO INDUCE AN IMMUNE **RESPONSE**

Enclos	ed are:					
\boxtimes	65 pag	ges of specification, 7 pages of claims, and an abstract				
		neet(s) of drawings				
\boxtimes	3 pages of an Oath or Declaration (unsigned)					
		Newly executed (original or copy)				
		A copy of oath or declaration filed with the prior application (37				
		C.F.R.§ 1.63(d))				
		The inventors to be deleted are set forth on a separate sheet attached				
		hereto				
\boxtimes	Nucleo	tide and/or Amino Acid Sequence Submission				
	\boxtimes	Computer Readable Copy				
	\boxtimes	Paper Copy (identical to computer copy), 31 pages				
	\boxtimes	Statement in compliance with 37 C.F.R.§ 1.821 verifying identity of above				
		copies				
	Other:					

		FILING	FEE			
	Claims	Number		Number		Basic Fee
For	Filed	allotted		Extra	Rate	\$740.00
Total Claims	59	20	=	39	\$18.00	\$ 702.00
Independent Claims	1	3	=	0	\$84.00	\$ 0.00
Multiple Dependent Clair				\$280.00		
TOTAL FILING FEE					\$1442.00	

\boxtimes	A check in the amount of $$1,442.00$ to cover \boxtimes filing fee and \square assignment recordal fee is enclosed.
-------------	---

Information from Prior Application:

Examiner: Not yet assigned

Art Unit: Not yet assigned

Prior Application Number: 09/958,713

SAS:jam 02/06/02 97610 Attorney Reference Number 4239-61997 **PATENT**

\bowtie	Assignee for this application is or will be The Government of the United States of America as represented by the Secretary of the Department of Health and Human			
	Services, and applicants request that this information be listed on the published application.			
	This is a continuation-in-part of U.S. Application No. 09/958,713 filed on October 11, 2001, which claims the benefit of PCT Application No. PCT/US00/09839 filed on April 12, 2000, which claims priority to U.S. Provisional Patent Application No. 60/128,898 filed on April 12, 1999, all of which are incorporated herein by reference in their entirety			
	Please charge our Deposit Account No. 02-4550 in the amount of Two copies of this sheet are enclosed.			
	The Director is hereby authorized to charge any additional fees which may be required in connection with the filing of this application and recording any assignment filed herewith, or credit over-payment, to Account No. 02-4550. A copy of this sheet is enclosed.			
\boxtimes	Please return the enclosed postcard to confirm that the items listed above have been received.			
	Respectfully submitted			

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

BySusan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600 121 S.W. Salmon Street Portland, Oregon 97204 Telephone: (503) 226-7391

Facsimile: (503) 228-9446

Docketing cc:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Klinman et al.

Application No. To be assigned

Filed: Herewith

For: OLIGODEOXYNUCLEOTIDE AND ITS

USE TO INDUCE AN IMMUNE

RESPONSE

Examiner: To be assigned

Date: February 6, 2002

Art Unit: To be assigned

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service on February 6, 2002 as First Class Mail in an envelope addressed to: BOX PATENT APPLICATION, COMMISSIONER FOR PATENTS,

WASHINGTON D.C. 20237.

Susan Alpert Siegel, Ph.D Agent for Applicant

STATEMENT IN COMPLIANCE WITH 37 C.F.R. § 1.821(f)

BOX PATENT APPLICATION COMMISSIONER FOR PATENTS WASHINGTON, DC 20231

Sir:

In compliance with 37 C.F.R. § 1.821(f), the undersigned declares that the nucleotide and/or amino acid sequences presented in the paper copy of the "Sequence Listing" submitted herewith are the same as the sequences contained in the computer-readable form of said "Sequence Listing."

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Susan Alpert Siegel, Ph.D. Registration No. 43,121

One World Trade Center, Suite 1600

121 S.W. Salmon Street Portland, Oregon 97204

Telephone: (503) 226-7391 Facsimile: (503) 228-9446